Eli-lilly-and

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets Wed, October 7, 2026 at 8:19 PM UTC Moderna and Eli Lilly led healthcare stocks high…

Moderna, Eli Lilly Lead Healthcare Stocks Higher on a Down Day for Markets

The healthcare sector stood out as one of the few bright spots in Wednesday's trading.

Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026?

JNJ trades at a 28% discount on valuation while LLY's cardiometabolic drugs drive 82% of revenue, each bet carries distinct growth and concentration risks.

Eli Lilly says closely watched combo obesity regimen boosts weight loss in mid-stage trial

Lilly said it plans to start Phase 3 trials on the combo regimen adding its amylin drug eloralintide to tirzepatide at the end of the year.

Novo is betting on its next chapter as Eli Lilly gains more ground in GLP-1s

As Novo works to turn itself around, some analysts say Lilly has advantages that could help it maintain its position at the top of the obesity drug market.

Eli Lilly breaks ground on $6.5B Houston manufacturing plant

Bechtel's manufacturing and technology business unit is supporting the project, according to a job posting from the Reston, Virginia-based general contractor.

FDA approves Eli Lilly's once-weekly insulin injection for type 2 diabetes

The once-weekly treatment could reduce the number of injections by more ⁠than 300 per year compared with once-daily basal insulin, Eli Lilly said.

Eli Lilly CEO says 700,000 new seniors have started GLP-1s after Medicare coverage, and 70% are on Lilly drugs

They're the latest metrics on how much the new Medicare coverage is expanding access to GLP-1 medicines since it launched in July.

What Eli Lilly Was Telling You While It Rationed Its Own Launches

Eli Lilly (LLY) stock has gained about 56% over the past year, moving from $722.65 to $1,123.91. Before that run the company was doing something strange. It wa…

Jim Cramer Picks J&J (JNJ) Over Eli Lilly (LLY) and Pfizer (PFE) Among These Healthcare Stocks

On September 3, a caller asked whether to rotate out of artificial intelligence stocks and add to Eli Lilly and Company (NYSE:LLY) rather than chase Johnson &…

What Is Shaping Interest in Eli Lilly Stock? (NYSE:LLY)

Eli Lilly (NYSE:LLY) is in focus after a verified corporate update, while sector conditions and broader market themes shape discussion around its operating cur…

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

The latest trading day saw Eli Lilly (LLY) settling at $1, representing a -2.21% change from its previous close.

Here's Why Eli Lilly (LLY) Fell More Than Broader Market

Eli Lilly (NYSE:LLY) Heads Into Conference Season With A Broadening Pipeline

Eli Lilly (NYSE:LLY) Heads Into Conference Season With A Broadening Pipeline

Lilly to buy Merida Biosciences for up to $2.88 billion in autoimmune drug push

Eli ⁠Lilly plans to buy privately held ⁠Merida Biosciences for ‌up to $2.88 billion in cash.

Eli Lilly and J&J bounce on new data, as software stocks give up last week's gains

Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.

Eli Lilly takes aim at illicit market for its experimental weight-loss drug

The pharmaceutical company is filing lawsuits against six outlets selling versions of its promising but unapproved weight-loss drug, retatrutide.

The divide between Eli Lilly and Novo Nordisk is widening after their latest earnings

As Lilly widens its lead in the obesity race, Novo is still racing to win back market share and restore investor confidence in its pipeline.

Stocks making the biggest moves premarket: SpaceX, AMD, Eli Lilly, Disney & more

These are the stocks posting the largest moves premarket.

Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge

Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion and $85 billion.